Nuheara (ASX:NUH) - Aandelenkoers, Nieuws & Analyse

NUH Overzicht aandelen

A wearables technology company, engages in the development and commercialization of hearing technology and products as regulated medical devices in Australia, the United States, and internationally.

Over het bedrijf

NUH fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst is de afgelopen 5 jaar met 11.8% per jaar gedaald

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

Heeft geen zinvolle omzet ( A$2M )

+ 2 meer risico's

Nuheara Limited Concurrenten

BirdDog Technology

ASX:BDT

AU$10.5m

Zimi

ASX:ZMM

AU$4.9m

ASX:TZL

AU$19.2m

Ambertech

ASX:AMO

AU$15.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Nuheara
Historische aandelenkoersen
Huidige aandelenkoers	AU$0.081
52 Week Hoogtepunt	AU$0.21
52 Week Laag	AU$0.07
Bèta	1.87
11 maand verandering	0%
3 maanden verandering	3.85%
1 Jaar Verandering	-42.14%
33 jaar verandering	-90.36%
5 jaar verandering	-94.53%
Verandering sinds IPO	-91.38%

Recent nieuws en updates

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Oct 09

Recent updates

Rendement voor aandeelhouders

	NUH	AU Tech	AU Markt
7D	0%	-2.5%	0.2%
1Y	-42.1%	19.2%	16.6%

Rendement versus industrie: NUH presteerde slechter dan de Australian Tech -sector, die het afgelopen jaar een rendement van 19.2 % opleverde.

Rendement versus markt: NUH presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 16.6 % opleverde.

Prijsvolatiliteit

Is NUH's price volatile compared to industry and market?
NUH volatility
NUH Average Weekly Movement	n/a
Tech Industry Average Movement	6.4%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.5%

Stabiele aandelenkoers: NUH heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van NUH in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	n/a	Justin Miller	www.nuheara.com

Nuheara Limited Samenvatting

Hoe verhouden de winst en inkomsten van Nuheara zich tot de beurswaarde?
NUH fundamentele statistieken
Marktkapitalisatie	AU$21.76m
Inkomsten(TTM)	-AU$12.62m
Inkomsten(TTM)	AU$1.93m

11.3x

P/S-verhouding

-1.7x

Koers/Winstverhouding

Is NUH overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NUH resultatenrekening (TTM)
Inkomsten	AU$1.93m
Kosten van inkomsten	AU$2.88m
Brutowinst	-AU$951.47k
Overige uitgaven	AU$11.67m
Inkomsten	-AU$12.62m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.047
Brutomarge	-49.27%
Nettowinstmarge	-653.33%
Schuld/Eigen Vermogen Verhouding	46.3%

Hoe presteerde NUH op de lange termijn?

Bekijk historische prestaties en vergelijking

NUH Overzicht aandelen

Beloningen

Risicoanalyse

Nuheara Limited Concurrenten

ASX:BDT

AU$10.5m

ASX:ZMM

AU$4.9m

ASX:TZL

AU$19.2m

ASX:AMO

AU$15.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Recent updates

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 1.850332 million.

Nuheara Limited Announces the Retirement of David Cannington as Non-Executive Director

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.929624 million.

New major risk - Shareholder dilution

Does Nuheara (ASX:NUH) Have A Healthy Balance Sheet?

Full year 2023 earnings released: AU$0.084 loss per share (vs AU$0.16 loss in FY 2022)

Nuheara Limited, Annual General Meeting, Nov 22, 2023

New major risk - Financial position

Nuheara Limited Announces Appointment of Catherine Morgan as Head of Compliance, Regulatory and Legal

New minor risk - Share price stability

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 4.4 million.

First half 2023 earnings released: AU$0.048 loss per share (vs AU$0.065 loss in 1H 2022)

Insufficient new directors

Nuheara Announces Commercial Availability of HP Hearing PRO OTC Hearing Aid

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 3.025401 million.

Nuheara Limited Receives US FDA Approval and Launches HP Hearing PRO

Nuheara Limited to Report Q1, 2023 Results on Oct 31, 2022

Nuheara Limited Announces the Resignation of Jean-Marie Rudd as CFO

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.10 loss in FY 2021)

Nuheara Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.15 loss per share (vs AU$0.093 loss in FY 2021)

Nuheara Limited Welcomes US Food and Drug Administration's Final Ruling, Establishing A Regulatory Category for Over-The-Counter (Otc) Hearing Aids in the United States

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Limited Announces Executive Changes

Nuheara Limited has filed an IPO in the amount of AUD 5 million.

Here's Why Nuheara (ASX:NUH) Must Use Its Cash Wisely

Nuheara Submits 510(k) for U.S. FDA Clearance

Nuheara Announces Executive Changes

Nuheara Limited Announces Successful Clinical Trial Self-Fitted Hearing Aids

Nuheara Limited to Report Q2, 2022 Results on Jan 31, 2022

Nuheara Clinical Trial and FDA 510(K) Pathway Update

We Think Nuheara (ASX:NUH) Needs To Drive Business Growth Carefully

Nuheara Limited Provides Update on Clinical Trial and Pathway to FDA 510(K) Approval

Is Nuheara (ASX:NUH) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.005 loss per share (vs AU$0.011 loss in FY 2020)

Nuheara Limited Receives U.S. FDA Registration and Hearing Aid Device Listing

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in 1H 2020)

What Can We Make Of Nuheara's (ASX:NUH) CEO Compensation?

Nuheara Limited has completed a Follow-on Equity Offering in the amount of AUD 11.5 million.

Nuheara Limited announced that it expects to receive AUD 11.5 million in funding

Nuheara Limited Appoints Warwick Sauer as Director

Is Nuheara (ASX:NUH) Using Debt In A Risky Way?

Nuheara Receives $2 Million Phase II Works with HP Inc

Full year earnings released - AU$0.011 loss per share

Nuheara Limited announced that it has received funding

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Nuheara Limited Samenvatting

11.3x

-1.7x

Inkomsten en omzet